PH80 PMD

Drug Profile

PH80 PMD

Alternative Names: ORG 39479; PH-80; PH80-PMD; PH80-PMD NS

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pherin Pharmaceuticals
  • Developer Pherin Pharmaceuticals; University of Pennsylvania
  • Class
  • Mechanism of Action Neurotransmitter receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Premenstrual syndrome

Most Recent Events

  • 17 Jun 2015 PH80 PMD is still in phase-II development for Premenstrual syndrome in USA
  • 27 Dec 2006 Results from a phase II trial in patients with Premenstrual syndrome have been added to the adverse events and Women's Health therapeutic trials sections
  • 18 Nov 1998 Phase-I clinical trials for Premenstrual syndrome in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top